Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy
Sponsor: Eli Lilly and Company
Summary
The purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration. Participation in the study will last approximately 7 months.
Official title: A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
84
Start Date
2025-11-18
Completion Date
2026-12
Last Updated
2026-03-09
Healthy Volunteers
Yes
Conditions
Interventions
LY4167586
Administered SC
Placebo
Administered SC
LY4167586
Administered IV
Locations (2)
Fortrea Clinical Research Unit
Madison, Wisconsin, United States
Lilly Centre for Clinical Pharmacology
Singapore, Singapore